Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 10% in Primary Immunodeficiency Replacement Therapy
2007-002611-27Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Dec 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Human normal immunoglobulin G in Immunogenetic disorder, sponsored by Octapharma. Primary endpoint: Safety of Octagam 10%. Started Dec 2007; status: terminated.
02
Drugs
Human normal immunoglobulin G
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2007-002611-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002611-27.